Case Report: Chemotherapy-Associated Systemic Sclerosis: Is DNA Damage to Blame?
DNA damage
chemotherapy
hematopoietic cell transplantation
scleroderma
systemic sclerosis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
01
2022
accepted:
31
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Systemic sclerosis, also known as scleroderma, is an autoimmune disease characterized by cutaneous and visceral fibrosis, immune dysregulation, and vasculopathy. Generally, the degree of skin fibrosis is associated with an increased likelihood of visceral organ involvement. Its pathogenesis is poorly understood; however, it is clear that changes in both the innate and adaptive immune responses are associated with fibroblast dysfunction and vascular damage. Further, DNA damage has been postulated as one of the triggering factors in systemic sclerosis, although the association of DNA damage with the progression of this disease is more poorly established. Recently, abnormal DNA damage response repair pathways have also been identified in patients with systemic sclerosis, suggesting that cells from patients with this disease may be more susceptible to DNA damaging agents. Chemotherapeutic drugs and other DNA damaging agents have been associated with the development of systemic sclerosis, as these agents may provide additional "hits" that promote abnormal DNA damage responses and subsequent inflammatory changes. Herein, we present the case of a 39-year-old female who developed scleroderma after the treatment of her breast cancer with chemotherapeutic agents. Her scleroderma was subsequently successfully treated with autologous hematopoietic stem cell transplantation. We also completed a literature review for previously published cases of chemotherapy associated with systemic sclerosis and highlighted a role of DNA damage in promoting the disease. Our case is the first case of chemotherapy associated with systemic sclerosis treated with hematopoietic stem cell transplantation.
Identifiants
pubmed: 35280883
doi: 10.3389/fmed.2022.855740
pmc: PMC8907619
doi:
Types de publication
Case Reports
Langues
eng
Pagination
855740Informations de copyright
Copyright © 2022 Du, Gniadecki, Storek and Osman.
Déclaration de conflit d'intérêts
RG receives speaker honoraria from Mallinckrodt. MO received speaker honoraria from Boehringer Ingelheim. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int Arch Occup Environ Health. 2010 Oct;83(7):763-9
pubmed: 20047060
Eur J Dermatol. 2016 Oct 1;26(5):427-443
pubmed: 27550571
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Clin Exp Dermatol. 2005 Mar;30(2):141-5
pubmed: 15725240
Cancer. 1995 Jul 1;76(1):110-5
pubmed: 8630861
J Autoimmun. 2010 Aug;35(1):52-7
pubmed: 20223638
Autoimmun Rev. 2014 Feb;13(2):151-6
pubmed: 24129037
Lancet Respir Med. 2020 Oct;8(10):963-974
pubmed: 32866440
J Dermatol. 2016 Sep;43(9):1071-4
pubmed: 26992088
J Dermatol. 2017 Apr;44(4):e54-e55
pubmed: 27600439
Pathophysiology. 2019 Jun;26(2):103-114
pubmed: 31130325
RMD Open. 2018 Jun 17;4(1):e000533
pubmed: 30018796
Acta Dermatovenerol Croat. 2016 Apr;24(1):78-80
pubmed: 27149136
Oncol Lett. 2011 Sep 1;2(5):769-772
pubmed: 22866124
N Engl J Med. 2018 Jan 4;378(1):35-47
pubmed: 29298160
Nat Rev Rheumatol. 2010 Dec;6(12):683-92
pubmed: 21060334
Nat Rev Rheumatol. 2018 Apr;14(4):189-191
pubmed: 29515186
Arthritis Res Ther. 2013;15(3):215
pubmed: 23796020
J Rheumatol. 2010 Dec;37(12):2540-7
pubmed: 20843906
Case Reports Immunol. 2017;2017:4249157
pubmed: 28265474
N Engl J Med. 2006 Apr 27;354(17):1813-26
pubmed: 16641398
Curr Opin Rheumatol. 2016 Sep;28(5):506-14
pubmed: 27227345
Int J Dermatol. 2018 Sep;57(9):1075-1079
pubmed: 29938783
Acta Derm Venereol. 2001 Nov-Dec;81(6):426-8
pubmed: 11859947
Int J Mol Sci. 2019 Dec 20;21(1):
pubmed: 31861764
Arthritis Rheumatol. 2016 Feb;68(2):299-311
pubmed: 26808827
Rheum Dis Clin North Am. 1992 Aug;18(3):539-50
pubmed: 1496160
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
JAMA. 1991 Jun 26;265(24):3292-5
pubmed: 2046111
Transplant Cell Ther. 2021 Jun;27(6):489.e1-489.e9
pubmed: 33775907
Scand J Rheumatol. 2001;30(4):185-8
pubmed: 11578009
J Am Acad Dermatol. 2004 Aug;51(2 Suppl):S73-6
pubmed: 15280817
Eur J Rheumatol. 2020 Oct;7(Suppl 3):S222-S227
pubmed: 33164736
J Dermatol. 2012 May;39(5):482-4
pubmed: 21955042
Self Nonself. 2011 Jan;2(1):4-10
pubmed: 21776329
Nat Genet. 2013 Nov;45(11):1284-92
pubmed: 24097067
J Am Acad Dermatol. 2003 Feb;48(2):279-81
pubmed: 12582404
J Rheumatol. 2007 Jan;34(1):97-103
pubmed: 17117485
Stem Cells Cloning. 2010 Aug 26;3:105-17
pubmed: 24198516
Front Immunol. 2015 Jun 08;6:272
pubmed: 26106387
Arch Dermatol. 1973 Apr;107(4):553-5
pubmed: 4121404
PLoS One. 2012;7(12):e51506
pubmed: 23284705
J Immunol. 2011 Nov 15;187(10):5336-45
pubmed: 22013119
Dermatol Reports. 2010 Jul 20;2(1):e9
pubmed: 25386245
Br J Dermatol. 2007 Feb;156(2):363-7
pubmed: 17223879
Rheumatology (Oxford). 2004 Jun;43(6):719-26
pubmed: 15026581
Nat Cell Biol. 2009 Aug;11(8):973-9
pubmed: 19597488
Curr Pathobiol Rep. 2014;2(4):257-267
pubmed: 25401052
J Rheumatol. 1992 Feb;19(2):294-6
pubmed: 1378497
Ann Rheum Dis. 2001 Jun;60(6):577-84
pubmed: 11350846
Front Immunol. 2020 Oct 02;11:582401
pubmed: 33123169
Autoimmun Rev. 2014 Jul;13(7):756-61
pubmed: 24657515
J Clin Med. 2020 Mar 20;9(3):
pubmed: 32245039
Clin Oncol (R Coll Radiol). 2012 Aug;24(6):452-3
pubmed: 22397832
EBioMedicine. 2019 Mar;41:185-199
pubmed: 30773478
Arthritis Rheum. 2001 Jun;44(6):1359-62
pubmed: 11407695